Peter Kolkhof
机构：Bayer (United States), Bayer (Germany) · ORCID：0000-0003-3425-7528
发表论文 177 篇 · 总被引 15062 次 · h-index 52
代表论文
- Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (2024 · New England Journal of Medicine · 被引 788)
- Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes (2024 · Nature Medicine · 被引 140)
- Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial (2024 · Nephrology Dialysis Transplantation · 被引 85)
- Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial (2023 · Diabetes Research and Clinical Practice · 被引 62)
- Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists (2023 · Journal of Clinical Investigation · 被引 42)
- Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF (2024 · Journal of the American College of Cardiology · 被引 40)